Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 May 30;14(5):1160-1164.
doi: 10.21037/tau-2024-755. Epub 2025 May 27.

Patient-centered outcomes and preference between darolutamide and enzalutamide: insights from the ODENZA trial

Guillaume Lim Fat  1 , Shabbir Alibhai  1
Affiliations
Editorial

Patient-centered outcomes and preference between darolutamide and enzalutamide: insights from the ODENZA trial

Guillaume Lim Fat et al. Transl Androl Urol. .
No abstract available

Keywords: Prostate cancer; anti-androgens; cognition; fatigue; treatment toxicities.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-2024-755/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Rice MA, Malhotra SV, Stoyanova T. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Front Oncol 2019;9:801. 10.3389/fonc.2019.00801 - DOI - PMC - PubMed
    1. Boué A, Joly F, Lequesne J, et al. Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis. Cancer 2024;130:2120-38. 10.1002/cncr.35210 - DOI - PubMed
    1. Batra A, Marchioni M, Hashmi AZ, et al. Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review. J Geriatr Oncol 2021;12:687-95. 10.1016/j.jgo.2020.11.002 - DOI - PubMed
    1. Nowakowska MK, Lei X, Wehner MR, et al. Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer. JAMA Netw Open 2021;4:e2140803. 10.1001/jamanetworkopen.2021.40803 - DOI - PMC - PubMed
    1. Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 2015;5:12007. 10.1038/srep12007 - DOI - PMC - PubMed